相关实验视频
Updated: Jun 30, 2025

04:23
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
304
萨尔科佩尼亚心力衰竭:从1995年到2022年的图书统计综述
Yaping You1, Tiantian Meng2, Xinyu Lu1
1Department of Cardiovascular Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Heliyon
|March 18, 2024
概括
关于患有肉类的心力衰竭的研究正在增长,重点是诊断,炎症等机制,以及运动和营养等治疗方法. 未来的热点包括临床试验和心脏康复.
科学领域:
- 心脏病学 心脏病学
- 老年病的医生 老年病的医生
- 生物医学研究生物医学研究
背景情况:
- 患有肉症的心力衰竭是一个新兴的临床挑战.
- 了解研究趋势对于推进该领域至关重要.
研究的目的:
- 动态跟踪研究重点,并识别心力衰竭与肉类的潜在热点.
- 分析出版趋势,关键机构和有影响力的研究人员.
主要方法:
- 使用CiteSpace对来自Web of Science数据库 (1995-2022) 的507个记录进行了图书统计分析.
- 关键词分析以确定核心研究主题和未来方向.
主要成果:
- 年度出版物的持续增长,欧洲和美国是领先的地区.
- 关键的研究领域包括诊断,潜在的机制 (炎症,胰岛素抵抗) 和治疗策略 (体育活动,营养).
- 确定了潜在的热点:临床试验,炎症机制,心脏康复和认知障碍结果.
结论:
- 心脏衰竭与sarcopenia的领域正在扩大,明确关注诊断标准,病理生理机制和治疗干预措施.
- 未来的研究应该优先考虑临床试验,炎症机制研究和全面的康复策略.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370

